^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    livmoniplimab (ABBV-151)

    i
    Other names: ABBV-151, ARGX 115, ARGX-115, ABBV 151
    Associations

    News

    Trials
    Company:
    AbbVie, argenx
    Drug class:
    TGF-β1 inhibitor, LRRC32 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=362, Recruiting, AbbVie | Trial primary completion date: Feb 2026 --> Jun 2027
    Trial primary completion date • Combination therapy • Metastases
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    2ms
    LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=840, Recruiting, AbbVie | Not yet recruiting --> Recruiting
    Enrollment open • Adverse events • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    2ms
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=337, Recruiting, AbbVie | Trial completion date: Feb 2026 --> Jun 2027
    Trial completion date • Combination therapy • Metastases
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    3ms
    LIVIGNO-4: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2/3, N=840, Not yet recruiting, AbbVie
    New P2/3 trial • Adverse events • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    5ms
    LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2/3, N=660, Recruiting, AbbVie | Not yet recruiting --> Recruiting | Phase classification: P2 --> P2/3
    Enrollment open • Phase classification • Adverse events • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    7ms
    LIVIGNO-2: A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov)
    P2, N=660, Not yet recruiting, AbbVie
    New P2 trial • Adverse events • Combination therapy • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab) • budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    7ms
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=337, Recruiting, AbbVie | Trial completion date: Apr 2024 --> Feb 2026 | Trial primary completion date: Apr 2024 --> Feb 2026
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    over2years
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, AbbVie | N=184 --> 260 | Trial primary completion date: Jul 2022 --> Apr 2023
    Clinical • Enrollment change • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • PGR negative
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    almost3years
    Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=184, Recruiting, AbbVie | Trial completion date: Jul 2022 --> Apr 2023
    Clinical • Trial completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • ER negative • PGR negative
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)
    almost4years
    [VIRTUAL] Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours (ESMO 2020)
    Funding: AbbVie Inc. Clinical trial identification: NCT03821935.
    Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    budigalimab (ABBV-181) • livmoniplimab (ABBV-151)